Evidence map›Paper›PMID 40656447›Full record

ArticleCochrane evidence synthesis and methods2025

Multiple Long-Term Conditions, Co-Long-Term Conditions and Polyvascular Disease: Considerations for Evidence Synthesis and Meta-Analyses.

Gillian Mead, Alex Todhunter-Brown, Ukachukwu Abaraogu, Amanda Barugh, Arohi Chauhan, Juan Erviti Lopez, Valery Feigin, Jaya Singh Kshatri, Atsushi Mizuno, Sanghamitra Pati and 8 more

Abstract read
In one paragraph

Article in Cochrane evidence synthesis and methods, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors.

Gillian MeadUsher Institute, University of Edinburgh Edinburgh UK.ORCID 0000-0001-7494-2023
Alex Todhunter-BrownGlasgow Caledonian University 70 Cowcaddens Road Glasgow G4 0BA UK.ORCID 0000-0003-4941-7985
Ukachukwu AbaraoguDivision of Biological Sciences and Health School of Health and Life Sciences University of the West of Scotland Scotland UK.ORCID 0000-0002-1967-1459
Amanda BarughUniversity of Edinburgh Edinburgh UK.
Arohi ChauhanSouth Asian Institute of Health Promotion Bhubaneswar Odisha India.ORCID 0000-0003-2439-7666
Juan Erviti LopezInnovation and Organization Unit, Navarre Health Service Pamplona Spain.
Valery FeiginNational Institute for Stroke & Applied Neurosciences, AUT University 55 Wellesley Street East Auckland City New Zealand.
Jaya Singh KshatriIndian Council of Medical Research, Regional Medical Research Centre Bhubaneswar India.ORCID 0000-0003-3616-3402
Atsushi MizunoDepartment of Cardiovascular Medicine St. Luke's International Hospital Tokyo Japan.ORCID 0000-0002-7596-7633
Sanghamitra PatiIndian Council of Medical Research New Delhi India.
Jackie PriceUsher Institute, University of Edinburgh Edinburgh UK.
Rui ProvidênciaInstitute of Health Informatics University College London 222 Euston Road London NW1 2DA UK.
Gerry StansbyFreeman Hospital, Newcastle Hospitals NHS Foundation Trust Freeman Road, High Heaton Newcastle upon Tyne NE7 7DN UK.
Rod TaylorSchool of Health and Wellbeing University of Glasgow Clarice Pears Building 90 Byres Road Glasgow G12 8TB UK.
David J WilliamsRCSI University of Medicine and Health Sciences Dublin Ireland UK.ORCID 0000-0002-1923-462X
James M WrightUniversity of BC Vancouver BC Canada.
Simiao WuDepartment of Neurology, West China Hospital Sichuan University Chengdu 610041 China.ORCID 0000-0002-4557-7386
Leon FlickerUniversity of Western Australia 35 Stirling Highway, Crawley Perth 6009 Australia.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Cochrane's scientific strategy for 2025 to 2030 has four research priorities, including improving the lives of people living with multiple chronic conditions. The purpose of this article written by the Cochrane Thematic Group in Heart, Stroke and Circulation is to explore considerations around multiple chronic conditions (also referred to as 'multiple long-term conditions' i.e. two or more long-term conditions) in systematic reviews. Rather than using the term 'comorbidity', we introduce a new term 'co-long-term conditions'. We also explore how to define 'polyvascular disease'. We suggest that review authors consider co-long-term conditions and multiple long-term conditions in their reviews e.g. extract data about how primary studies address co-long-term conditions, perform subgroup analyses according to presence or not of co-long-term conditions, and include a section in the discussion about how well participants with co-long-term conditions were represented in the primary studies. This is especially pertinent for reviews addressing heart, circulatory or stroke disease, and polyvascular disease.

Identifiers

PMID40656447
PMCPMC12245129

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.